Our findings establish a novel radiogenomic strategy that bridges MRI-derived imaging phenotypes with molecular mechanisms. FIBCD1 may serve as an immune-modulating prognostic biomarker linked to imaging characteristics, providing new insights into non-invasive breast cancer risk assessment and therapeutic targeting.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: